Merck has struck a deal worth up to $1.3 billion to buy an investigational drug targeting B-cell associated diseases.
Related Posts
Tractor Supply Updates Long-Term Financial Targets, Announces Stock Split
The rural-lifestyle retailer said it is aiming to increase net sales by between 6% and 8%, same-store sales by between 3% and 5% and per-share […]
Tesla Reports Higher Profit in Third Quarter
The surprise increase was the first since the electric-car maker’s earnings began to slide earlier this year as it turned to deep price cuts and […]
JD.com Profit Nearly Doubles as Revenue Rises
Chinese e-commerce giant JD.com’s second quarter net profit rose 92%, while revenue grew slightly amid fierce competition from Alibaba Group and PDD Holdings.